Validating the DemTect with 18-fluoro-2-deoxy-glucose positron emission tomography as a sensitive neuropsychological screening test for early Alzheimer disease in patients of a memory clinic

Dementia and Geriatric Cognitive Disorders

Volumn 20, Issue 5, 2005, Pages 271-277

  Scheurich, Armin ^a   Müller, Matthias J ^a   Siessmeier, Thomas ^a   Bartenstein, Peter ^a   Schmidt, Lutz G ^a   Fellgiebel, Andreas ^a  

^a JOHANNES GUTENBERG UNIVERSITY   (Germany)

Author keywords

Dementia screening; DemTect; FDG PET; Neuropsychology

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

AGED; ALZHEIMER DISEASE; ARTICLE; CLINICAL ARTICLE; COGNITIVE DEFECT; CONTROLLED STUDY; DEMTECT; DIAGNOSTIC ACCURACY; DIAGNOSTIC APPROACH ROUTE; EARLY DIAGNOSIS; FEMALE; GLUCOSE BRAIN LEVEL; GLUCOSE METABOLISM; HUMAN; INSTRUMENT; INTERMETHOD COMPARISON; MALE; MENTAL HEALTH CENTER; NEUROPSYCHOLOGICAL TEST; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RATING SCALE; REFERENCE VALUE; SCORING SYSTEM; SCREENING TEST; VALIDATION PROCESS;

AGED; ALZHEIMER DISEASE; COGNITION; DATA INTERPRETATION, STATISTICAL; FEMALE; FLUORODEOXYGLUCOSE F18; HUMANS; INFARCTION, MIDDLE CEREBRAL ARTERY; MALE; MEMORY; MENTAL RECALL; MIDDLE AGED; NEUROPSYCHOLOGICAL TESTS; POSITRON-EMISSION TOMOGRAPHY; RADIOPHARMACEUTICALS; ROC CURVE;

EID: 26644467933     PISSN: 14208008     EISSN: None     Source Type: Journal    
DOI: 10.1159/000088248     Document Type: Article

References (20)

1. Berent S, Giordani B, Foster N, Minoshima S, Lajiness-O'Neill R, Koeppe R, Kuhl DE: Neuropsychological function and cerebral glucose utilization in isolated memory impairment and Alzheimer's disease. J Psychiatr Res 1999;33:7-16.
2. Rasquin SM, Lodder J, Visser PJ, Lousberg R, Verhey FR: Predictive accuracy of MCI subtypes for Alzheimer's disease and vascular dementia in subjects with mild cognitive impairment: a 2-year follow-up study. Dement Geriatr Cogn Disord 2005;19:113-119.
3. Petersen RC, Smith GE, Waring SC, Ivnik RJ, Tangalos EG, Kokmen E: Mild cognitive impairment: clinical characterization and outcome. Arch Neurol 1999;56:303-308.
4. Laakso MP, Hallikainen M, Hanninen T, Partanen K, Soininen H: Diagnosis of Alzheimer's disease: MRI of the hippocampus vs delayed recall. Neuropsychologia 2000;38:579-584.
5. Locascio JJ, Growdon JH, Corkin S: Cognitive test performance in detecting, staging, and tracking Alzheimer's disease. Arch Neurol 1995;52:1087-1099.
6. Welsh K, Butters N, Hughes J, Mohs R, Heyman A: Detection of abnormal memory decline in mild cases of Alzheimer's disease using CERAD neuropsychological measures. Arch Neurol 1991;48:278-281.
7. Folstein MF, Folstein SE, McHugh PR: 'Minimental state'. A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189-198.
8. Kukull WA, Larson EB, Teri L, Bowen J, McCormick W, Pfanschmidt ML: The Mini-Mental State Examination score and the clinical diagnosis of dementia. J Clin Epidemiol 1994;47:1061-1067.
9. Kessler J, Calabrese P, Kalbe E, Berger F: DemTect: a new dementia screening instrument. Psycho 2000;26:343-347.
10. Kalbe E, Kessler J, Calabrese P, Smith R, Passmore AP, Brand M, Bullock R: DemTect: a new, sensitive cognitive screening test to support the diagnosis of mild cognitive impairment and early dementia. Int J Geriatr Psychiatry 2004;19:136-143.
11. Silverman DH, Small GW, Chang CY, Lu CS, Kung De Aburto MA, Chen W, Czernin J, Rapoport SI, Pietrini P, Alexander GE, Schapiro MB, Jagust WJ, Hoffman JM, Welsh-Bohmer KA, Alavi A, Clark CM, Salmon E, de Leon MJ, Mielke R, Cummings JL, Kowell AP, Gambhir SS, Hoh CK, Phelps ME: Positron emission tomography in evaluation of dementia: regional brain metabolism and long-term outcome. JAMA 2001;286:2120-2127.
12. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984;34:939-944.
13. Chetelat G, Desgranges B, de la Sayette V, Viader F, Eustache F, Baron JC: Mild cognitive impairment: can FDG-PET predict who is to rapidly convert to Alzheimer's disease? Neurology 2003;60:1374-1377.
14. Drzezga A, Lautenschlager N, Siebner H, Riemenschneider M, Willoch F, Minoshima S, Schwaiger M, Kurz A: Cerebral metabolic changes accompanying conversion of mild cognitive impairment into Alzheimer's disease: a PET follow-up study. Eur J Nucl Med Mol Imaging 2003;30:1104-1113.
15. Schmidt R, Fazekas F, Kleinert G, Offenbacher H, Gindl K, Payer F, Freidl W, Niederkorn K, Lechner H: Magnetic resonance imaging signal hyperintensities in the deep and subcortical white matter. A comparative study between stroke patients and normal volunteers. Arch Neurol 1992;49:825-827.
16. Petersen RC, Doody R, Kurz A, Mohs RC, Morris JC, Rabins PV, Ritchie K, Rossor M, Thal L, Winblad B: Current concepts in mild cognitive impairment. Arch Neurol 2001;58:1985-1992.
17. Minoshima S, Frey KA, Koeppe RA, Foster NL, Kuhl DE: A diagnostic approach in Alzheimer's disease using three-dimensional stereotactic surface projections of fluorine-18-FDG PET. J Nucl Med 1995;36:1238-1248.
18. 18F-fluoro-2-deoxy-D-glucose positron emission tomography findings in patients with mild cognitive impairment. Biol Psychiatry 2004;56:279-283.
19. Busse A, Bischkopf J, Riedel-Heller SG, Angermeyer MC: Subclassifications for mild cognitive impairment: prevalence and predictive validity. Psychol Med 2003;33:1029-1038.
20. Kalbe E, Kessler J, Smith R, Bullock R, Fischer L, Calabrese P: DemTect: a new screening instrument with very high sensitivity for vascular and Alzheimer dementia; in Korczyn A (ed): Proceedings of the 2nd International Congress on Vascular Dementia, 2002, Jan 24-27; Salzburg, Austria. Bologna, Monduzzi, 2002.